医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

159938 医药

已收盘 01-21 15:00:00

{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.675,"timestamp":1768979034000,"preClose":0.678,"halted":0,"volume":463441574,"delay":0,"changeRate":-0.0044,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.003,"latestTime":"01-21 15:00:00","open":0.675,"high":0.683,"low":0.673,"amount":313000000,"amplitude":0.0147,"askPrice":0.675,"askSize":161,"bidPrice":0.674,"bidSize":4922,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.678,"symbolType":"fund","openAndCloseTimeList":[[1768959000000,1768966200000],[1768971600000,1768978800000]],"highLimit":0.746,"lowLimit":0.61,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.287269,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2605174823","title":"华兰股份(301093.SZ)拟斥4.5亿元增资灵擎数智 完善AI医药领域战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2605174823","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605174823?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:20","pubTimestamp":1768983652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华兰股份(301093.SZ)公告，公司董事会审议通过了《关于向全资子公司增资的议案》。海南灵擎数智医药科技有限公司(简称“灵擎数智”)为公司全资子公司，系公司在AI医药领域的重要业务布局平台，主要聚焦于人工智能创新药研发解决方案及服务，助力人工智能技术在药物研发及产业应用等方向的研发与商业化推进。公司将以自有资金4.5亿元对全资子公司灵擎数智进行增资。公告称，本次增资有利于公司进一步完善在AI医药领域的战略布局，强化公司在相关前沿技术领域的持续投入能力和产业协同能力，有助于推动公司AI医药业务的稳步发展和商业化落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK0239","BK1161","BK1515","BK1574","159938","301093"],"gpt_icon":0},{"id":"2605178650","title":"北京新增23家村卫生室定点医药机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2605178650","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605178650?lang=zh_cn&edition=full","pubTime":"2026-01-21 13:51","pubTimestamp":1768974660,"startTime":"0","endTime":"0","summary":"北京市东四中医医院等6家定点医药机构，因不能继续为参保人员提供服务，被中止医保服务协议。北京市海淀区西三旗街道永泰社区卫生服务站等36家定点医药机构，因已注销、镇村两级医疗机构医保服务一体化管理等原因，被解除医保服务协议，将不再承担医疗保障任务。","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2026/01/21/5678039304090232254.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/01/21/5678039304090232254.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1768974410129295.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1768974410129295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1574","159938","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2604418542","title":"1月19日博腾股份跌5.06%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604418542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604418542?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:41","pubTimestamp":1768808505,"startTime":"0","endTime":"0","summary":"证券之星消息，1月19日博腾股份跌5.06%，收盘报26.45元，换手率3.77%，成交量18.82万手，成交额5.03亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为7.87亿元，最新净值1.1766，较上一交易日下跌0.7%，近一年上涨65.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900014550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0028","BK1574","300363","BK0239","159938","BK1161"],"gpt_icon":0},{"id":"2604490718","title":"勤浩医药冲刺港股上市，华泰国际为保荐人","url":"https://stock-news.laohu8.com/highlight/detail?id=2604490718","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604490718?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:36","pubTimestamp":1768800960,"startTime":"0","endTime":"0","summary":"近日，勤浩医药向港交所主板递交上市申请书，由华泰国际保荐。招股书显示，公司专注于开发肿瘤学领域的潜在同类最佳靶向疗法，其核心技术围绕RAS信号通路及合成致死机制。截至最后实际可行 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260119/c674115134.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260119/c674115134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"gpt_icon":0},{"id":"2604753239","title":"新股消息 | 勤浩医药递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2604753239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604753239?lang=zh_cn&edition=full","pubTime":"2026-01-18 20:27","pubTimestamp":1768739258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所1月16日披露，勤浩医药(苏州)股份有限公司-B向港交所主板递交上市申请书，华泰国际为其独家保荐人。该公司是一家生物制药公司，拥有围绕RAS信号通路及合成致死机制打造的、具有差异化且强大的自主开发创新候选药物管线。根据灼识咨询的资料，就同一靶点的临床进展而言，该公司的多款候选药物处于全球领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","09939","159938","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2604692549","title":"每周股票复盘：百奥泰（688177）获吉瑞医药250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2604692549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604692549?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:14","pubTimestamp":1768680849,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，百奥泰报收于25.07元，较上周的25.51元下跌1.72%。本周，百奥泰1月13日盘中最高价报26.33元。协议首付款及里程碑款总额最高达1.10亿美元，包括850万美元首付款和不超过1.015亿美元的里程碑付款，另加净销售额的两位数百分比分成。公司近日收到吉瑞医药支付的250万美元里程碑款，实际到账金额扣除银行手续费。BAT2206已在美欧获批上市，商品名分别为STARJEMZA和Usymro，中国上市申请正在评审中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","159938","BK1515","BK1574","09939","BK0239","BK1161"],"gpt_icon":0},{"id":"2604328942","title":"勤浩医药冲刺港股：9个月亏损近1亿 王奎锋控制40%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2604328942","media":"雷递","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604328942?lang=zh_cn&edition=full","pubTime":"2026-01-17 11:58","pubTimestamp":1768622280,"startTime":"0","endTime":"0","summary":"9个月亏损近1亿勤浩医药主要专注于开发肿瘤学领域的潜在同类最佳靶向疗法。勤浩医药于2021年11月从国家药监局获得GH21单药治疗晚期实体瘤的IND批准，于2022年5月开始其1期单药治疗临床试验，并于2025年3月获得临床研究报告从而完成1期临床试验。招股书显示，勤浩医药2024年营收为469万元，毛利为231万元，期内亏损为1.52亿元；2025年前9个月营收为98万元，期内亏损为9889万元。截至2025年9月30日，勤浩医药持有的现金及现金等价物为813.6万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzQ5NjIyMQ==&mid=2661663407&idx=5&sn=bb3bcf664eb68eb87fa56a46d1c8fd23&chksm=bdc74f5d8ab0c64bfe119b67326c7c2335723147249224018a67b3810f1d850cd23ad307d412#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159938"],"gpt_icon":0},{"id":"2603979869","title":"【新股IPO】勤浩医药(苏州)股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2603979869","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603979869?lang=zh_cn&edition=full","pubTime":"2026-01-16 23:44","pubTimestamp":1768578283,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所1月16日披露，勤浩医药 股份有限公司向港交所主板提交上市申请，华泰国际为其独家保荐人。公司是一家生物制药公司，拥有围绕RAS信号通路及合成致死机制打造的、具有差异化且强大的自主开发创新候选药物管线。财务方面，于2024年及2025年截至9月30日止九个月，公司研发成本为1.03亿元、5764.9万元；对应同期，亏损及全面亏损总额为1.52亿元、9888.7万元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973415","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","09939","BK1161","BK1515","HEXmain"],"gpt_icon":0},{"id":"2603994075","title":"森萱医药（920946）披露预计2026年度日常关联交易议案，1月16日股价下跌1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994075?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:45","pubTimestamp":1768574714,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，森萱医药报收于11.08元，较前一交易日下跌1.34%，最新总市值为47.3亿元。该股当日开盘11.26元，最高11.35元，最低11.08元，成交额达4413.6万元，换手率为0.93%。近日，江苏森萱医药股份有限公司召开2026年第一次临时股东会，审议通过《关于预计2026年度日常关联交易的议案》。议案获得同意股数占比99.930824%，关联股东精华制药集团股份有限公司已回避表决。中小股东对该议案的同意比例为99.929884%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2603951749","title":"吉林敖东：智能化驱动医药全产业链升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603951749?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:52","pubTimestamp":1768567945,"startTime":"0","endTime":"0","summary":"证券之星消息，吉林敖东01月16日在投资者关系平台上答复投资者关心的问题。公司积极关注AI与医药及健康领域深度融合带来的产业变革。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600038785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0012","BK1161","09939","BK1515","BK0188","BK0074","BK0239","BK1574","BK0201","BK0028","000623","BK0086"],"gpt_icon":0},{"id":"2603789968","title":"1月16日三博脑科跌7.94%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603789968","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603789968?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:42","pubTimestamp":1768549378,"startTime":"0","endTime":"0","summary":"证券之星消息，1月16日三博脑科跌7.94%，收盘报82.21元，换手率18.69%，成交量30.08万手，成交额25.41亿元。重仓三博脑科的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为5.03亿元，最新净值0.634，较上一交易日下跌1.2%，近一年上涨31.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600019563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0236","BK1161","159938","301293","BK1515","09939"],"gpt_icon":0},{"id":"2603674599","title":"1月15日三博脑科跌5.78%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603674599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603674599?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:42","pubTimestamp":1768462971,"startTime":"0","endTime":"0","summary":"证券之星消息，1月15日三博脑科跌5.78%，收盘报89.3元，换手率20.35%，成交量32.75万手，成交额30.04亿元。重仓三博脑科的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为5.03亿元，最新净值0.6417，较上一交易日上涨0.06%，近一年上涨32.31%。该公募基金现任基金经理为方伟。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500020089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","301293","09939","BK0236","BK1574","BK1515","159938"],"gpt_icon":0},{"id":"2603676541","title":"亦诺微医药递表港交所，致力于开发新型溶瘤免疫疗法和工程化外泌体疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2603676541","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603676541?lang=zh_cn&edition=full","pubTime":"2026-01-15 14:32","pubTimestamp":1768458720,"startTime":"0","endTime":"0","summary":"近日，亦诺微医药港股IPO申请获得受理，招股书正式公开。亦诺微致力于开发新型溶瘤免疫疗法和工程化外泌体疗法，已经建立起包括2款溶瘤病毒疗法和5款外泌体疗法的管线。招股书显示，亦诺微 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260115/c674037099.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260115/c674037099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"gpt_icon":0},{"id":"2603462732","title":"楚天科技：子公司专注医药智能机器人领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2603462732","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603462732?lang=zh_cn&edition=full","pubTime":"2026-01-15 11:33","pubTimestamp":1768448014,"startTime":"0","endTime":"0","summary":"证券之星消息，楚天科技(300358)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，贵公司在人型机器人方面是否有业务开展，谢谢！楚天科技回复：您好！公司专注于为全球医药客户提供自动化、智能化整体解决方案，相关业务及技术拓展围绕着技术同心圆、客户同心圆和产品同心圆展开。子公司楚天智能机器人目前同样专注于医药、医用及技术同心圆等相关领域，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500015452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","BK0028","300358","BK0077","159938","BK1161","BK0251","BK0061","09939"],"gpt_icon":0},{"id":"2603626967","title":"【券商聚焦】交银国际：JPM医药大会有望继续催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2603626967","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603626967?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:09","pubTimestamp":1768439355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周26省联盟药品集采开启，纳入多项国采可替代品种，该机构认为具备成本与渠道优势的头部企业将获益；同时两大进口主导型耗材省际联盟集采启动，国产替代进程有望进一步提速。JPM医药大会将于本周召开，超20家中国公司将出席并发表主题演讲，有望继续催化行情。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973261","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU0238689110.USD","BK4207","LU1116320737.USD","LU2430703095.HKD","03329","LU0345770308.USD","LU1064131342.USD","06160","09688","LU1670628061.USD","SG9999004311.SGD","02268","01099","IE00BN8TJ469.HKD","LU1496350171.SGD","LU0942090050.USD","IE00BWXC8680.SGD","02196","09926","IE00B5MMRT66.SGD","BK4581","02367","LU0211327993.USD","LU2357305700.SGD","09939","LU0496365809.HKD","LU0267386448.USD","LU0307460666.USD","BK1141","LU1719994722.HKD","BK1197","BK1593","LU0640798160.USD","LU2592432038.USD","LU0310799852.SGD","03933","159938","01530","LU0868494617.USD","LU1280957306.USD","LU1032466523.USD","LU1988902786.USD","LU0215105999.USD","BK1515","01789","LU0820561909.HKD","LU2505996681.GBP"],"gpt_icon":0},{"id":"2603640901","title":"新股消息 | 亦诺微医药递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2603640901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603640901?lang=zh_cn&edition=full","pubTime":"2026-01-15 06:36","pubTimestamp":1768430214,"startTime":"0","endTime":"0","summary":"据悉，亦诺微医药曾于2025年6月25日向港交所主板提交上市申请。招股书披露，亦诺微医药是一家专注于临床需求导向的生物科技公司，致力于发现、开发、生产及商业化新型溶瘤免疫疗法和工程化外泌体疗法。公司已建立一条产品管线，包括：两款针对实体瘤的溶瘤免疫疗法产品，及 五款具临床应用前景或可直接商业化的工程化外泌体产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","159938","BK1515","BK1161","HEXmain"],"gpt_icon":0},{"id":"2603640558","title":"【ETF动向】1月14日平安医药及医疗器械创新ETF基金跌0.78%，份额增加1.06亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603640558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603640558?lang=zh_cn&edition=full","pubTime":"2026-01-15 06:31","pubTimestamp":1768429909,"startTime":"0","endTime":"0","summary":"证券之星消息，1月14日，平安医药及医疗器械创新ETF基金（516820）跌0.78%，成交额1.41亿元。当日份额增加了1.06亿份，最新份额为46.28亿份，近20个交易日份额增加2.22亿份。当日资金净流入2620.75万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为17.56亿元。平安医药及医疗器械创新ETF基金跟踪标的为中证医药及医疗器械创新指数，成立（2021-06-09）以来超额回报为2.07%，近一个月超额回报为0.29%，管理人为平安基金公司，基金经理为翁欣 白圭尧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500004072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1161","BK1515","BK1100","09997","BK1222","09996","159987","BK1574","BK1583","159938","09939"],"gpt_icon":0},{"id":"2603902666","title":"连续9年跑赢行业指数，易方达杨桢霄穿越医药周期的双轮法则","url":"https://stock-news.laohu8.com/highlight/detail?id=2603902666","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603902666?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:33","pubTimestamp":1768390380,"startTime":"0","endTime":"0","summary":"　　步入2026年，A股开门红势头强劲，此前调整多时的医药板块也再度重整旗鼓；　　自现任基金经理杨桢霄2016年8月管理易方达医疗保健以来，其任职回报达237.49%，年化收益13.81%，长期业绩优异。　　更为难得的是，据投资报统计，该基金自2017年以来连续9个完整年度跑赢医药生物指数，稳定取得超额收益；　　作为一只行业基金，能持续战胜行业指数实属不易，体现出了基金经理的价值所在。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjyj/2026-01-14/doc-inhhhtei4864373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","159938","BK1161","09939"],"gpt_icon":0},{"id":"2603988636","title":"1月14日博腾股份涨7.30%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603988636?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:39","pubTimestamp":1768376379,"startTime":"0","endTime":"0","summary":"证券之星消息，1月14日博腾股份涨7.30%创60日新高，收盘报29.41元，换手率8.34%，成交量41.6万手，成交额12.02亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为7.87亿元，最新净值1.1856，较上一交易日上涨2.54%，近一年上涨69.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","BK0028","BK1574","BK1161","09939","159938","300363"],"gpt_icon":0},{"id":"2603660738","title":"东北证券：医药出海向全球价值链中高端迈进 国内逐步回归稳健成长","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660738?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:28","pubTimestamp":1768375696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东北证券发布研报称，国内市场历经多年的高速放量，在医保资金压力凸显、医保支付改革全面落地的大背景下，逐步回归稳健成长;设备与耗材的全面集采倒逼企业寻找新利润增长点，“出海”已是国产先进厂商的战略必然。迈瑞医疗是IVD出海突出代表，公司持续推进营销网络与供应链的全球化布局，持续并购并与公司既有网络整合，海外业绩持续兑现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK0276","BK0028","BK1515","159938","000686","BK1161","BK0188","BK1574","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768999389889,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":0.0211},{"period":"3month","weight":-0.0383},{"period":"6month","weight":-0.0245},{"period":"1year","weight":0.1511},{"period":"ytd","weight":0.0447}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0574},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1409},{"period":"1year","weight":0.2679},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}